Influenza A H1N1 influenza vaccine safety and immunogenicity of a preliminary study.docVIP

 PAGE \* MERGEFORMAT 16 Influenza A H1N1 influenza vaccine safety and immunogenicity of a preliminary study Of: Zhuangmao Xin Fu Cui Yingjie Pan Hongxing Jiang Wei Zhang Xuefeng Wang Meng Yue Zhou Yuchun Hu Xiaokui ZHU Feng Yao was the root of red [Abstract] Objective: To evaluate the cracking of domestic swine influenza virus H1N1 vaccine clinical safety and immunogenicity. Methods: According to randomized, controlled, blind principle, choose the old age (60 years old, Junior (12 to 17 age group and children (3 to 11 years old group of 220 people, according to the proportion of 1 ?U 1 15,30 g influenza H1N1 were inoculated with influenza vaccine, adult (18 to 60 age group of 330 people, according to the proportion of 1 ?U 1 ?U 1 were inoculated 15,30 g Influenza A H1N1 influenza vaccine and placebo controls. Comparison of two doses of vaccine the overall rate of adverse events after immunization, systemic and local adverse reaction rate, HI antibody positive rate, HI antibody (gt; = 1 ?U protection rate of 40 persons, after the HI-free HI antibody after immunization antibody GMT and GMT times higher than the average growth before free. Results: After the free 21 d, each dose group of adverse reactions collected 10.81% of total incidence rate (107/990, are an adverse reaction-based, not observed three or more adverse events. Safety Observation other abnormalities were not observed during the reaction, coupling reaction and the clinical significance of any serious adverse events .30,15 g of HI antibody positive rates were 87.24%, 84.45%, No significant differences were significantly higher than the placebo control group HI antibody positive rate, HI antibody (gt; = 1 ?U 40 for the Protection of 87.94%, respectively, and 85.61%, the difference was not statistically significant, were significantly higher than placebo HI antibody in the control group rate of protection, after-free group was higher than HI antibody GMT 30g 15g group, 15g group than the placebo